- 公司资讯
- finviz | 2019年08月09日 21:00CytRx Corporation Reports Second Quarter 2019 Financial Results
- finviz | 2019年07月30日 21:00CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
- finviz | 2019年07月22日 21:00CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
- finviz | 2019年06月27日 20:00CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
- finviz | 2019年06月26日 21:00CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
- finviz | 2019年06月22日 04:52Nasdaq delists shares of FTD, Insys, others
- finviz | 2019年06月19日 21:00CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
- finviz | 2019年05月31日 21:00CytRx Corporation to Commence Trading on OTCQB Venture Market
- finviz | 2019年05月15日 21:05CytRx: 1Q Earnings Snapshot
- finviz | 2019年05月15日 21:00CytRx Corporation Reports First Quarter 2019 Financial Results
- finviz | 2019年05月08日 21:00CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
- finviz | 2019年05月02日 21:00CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
- finviz | 2019年04月29日 21:00CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
- finviz | 2019年03月29日 21:00CytRx Corporation Reports 2018 Financial Results
- finviz | 2019年03月12日 21:00CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
- finviz | 2019年02月13日 21:00CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR Technology Targeting Delivery Directly to the Tumor
首页
上页
下页